[
  {
    "ts": null,
    "headline": "Johnson & Johnson Scores With Heart Pump Breakthrough",
    "summary": "Clinical trial shows 16% mortality drop as $55 billion expansion plan unfolds",
    "url": "https://finnhub.io/api/news?id=c90f7de9c46844484d198f73b608e0be44e492ca76092ff6a0b90a4f1048f599",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756846432,
      "headline": "Johnson & Johnson Scores With Heart Pump Breakthrough",
      "id": 136612894,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Clinical trial shows 16% mortality drop as $55 billion expansion plan unfolds",
      "url": "https://finnhub.io/api/news?id=c90f7de9c46844484d198f73b608e0be44e492ca76092ff6a0b90a4f1048f599"
    }
  },
  {
    "ts": null,
    "headline": "VONV: Well Balanced Value ETF, But Lagging Some Peers",
    "summary": "Read the latest analysis on Vanguard Russell 1000 Value, and ETF that tracks the Russell 1000 Value Index.",
    "url": "https://finnhub.io/api/news?id=538092aaa36f305485a3b8808220ae8ab955999fb6a707bf58c7ae91eed47d8c",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756826067,
      "headline": "VONV: Well Balanced Value ETF, But Lagging Some Peers",
      "id": 136607576,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1203706408/image_1203706408.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "Read the latest analysis on Vanguard Russell 1000 Value, and ETF that tracks the Russell 1000 Value Index.",
      "url": "https://finnhub.io/api/news?id=538092aaa36f305485a3b8808220ae8ab955999fb6a707bf58c7ae91eed47d8c"
    }
  },
  {
    "ts": null,
    "headline": "Glaukos Builds Dual Growth Engines Amid Market Headwinds",
    "summary": "GKOS raises revenue guidance after record 1H sales, fueled by iDose TR adoption and expanding international glaucoma momentum.",
    "url": "https://finnhub.io/api/news?id=1f8e00f7346eff4cb746a82fc6d604555357227e9739e0c7235338bfefc7ef7a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756825800,
      "headline": "Glaukos Builds Dual Growth Engines Amid Market Headwinds",
      "id": 136612895,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "GKOS raises revenue guidance after record 1H sales, fueled by iDose TR adoption and expanding international glaucoma momentum.",
      "url": "https://finnhub.io/api/news?id=1f8e00f7346eff4cb746a82fc6d604555357227e9739e0c7235338bfefc7ef7a"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly's New Drugs Beyond Mounjaro and Zepbound Boost Sales",
    "summary": "Eli Lilly's growing lineup beyond Mounjaro and Zepbound, including Omvoh and Jaypirca, is set to fuel revenue growth through 2025.",
    "url": "https://finnhub.io/api/news?id=f7b8a5b03937a6c38486617ec514d6c3f02ebf94ec57448fba034c5c55d8e281",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756825260,
      "headline": "Eli Lilly's New Drugs Beyond Mounjaro and Zepbound Boost Sales",
      "id": 136612878,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Eli Lilly's growing lineup beyond Mounjaro and Zepbound, including Omvoh and Jaypirca, is set to fuel revenue growth through 2025.",
      "url": "https://finnhub.io/api/news?id=f7b8a5b03937a6c38486617ec514d6c3f02ebf94ec57448fba034c5c55d8e281"
    }
  },
  {
    "ts": null,
    "headline": "Nicotine Gum Market Report 2025-2033 | Competitive Analysis of British American Tobacco, Cambrex, GlaxoSmithKline, ITC, Johnson & Johnson, Novartis, Perrigo, Pfizer, and Takeda",
    "summary": "The nicotine gum market is driven by smoking cessation initiatives and rising health awareness, leading to increased demand for OTC nicotine therapies. Technological advancements enhance product efficacy, and North America leads the market due to health-conscious consumers. Challenges include overcoming social stigmas. Nicotine Gum Market Nicotine Gum Market Dublin, Sept. 02, 2025 (GLOBE NEWSWIRE) -- The \"Nicotine Gum Market Report by Type, and Region 2025-2033\" has been added to ResearchAndMark",
    "url": "https://finnhub.io/api/news?id=33c9ebbab7aeb6d59e547832b4b661f2535bd8fb6e6c7545c0a056616208f8ff",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756824300,
      "headline": "Nicotine Gum Market Report 2025-2033 | Competitive Analysis of British American Tobacco, Cambrex, GlaxoSmithKline, ITC, Johnson & Johnson, Novartis, Perrigo, Pfizer, and Takeda",
      "id": 136612897,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "The nicotine gum market is driven by smoking cessation initiatives and rising health awareness, leading to increased demand for OTC nicotine therapies. Technological advancements enhance product efficacy, and North America leads the market due to health-conscious consumers. Challenges include overcoming social stigmas. Nicotine Gum Market Nicotine Gum Market Dublin, Sept. 02, 2025 (GLOBE NEWSWIRE) -- The \"Nicotine Gum Market Report by Type, and Region 2025-2033\" has been added to ResearchAndMark",
      "url": "https://finnhub.io/api/news?id=33c9ebbab7aeb6d59e547832b4b661f2535bd8fb6e6c7545c0a056616208f8ff"
    }
  },
  {
    "ts": null,
    "headline": "Grand River Aseptic Manufacturing (GRAM) Appoints Denis Johnson as Chief Executive Officer",
    "summary": "Effective September 1, 2025 Denis Johnson, CEO Denis Johnson, CEO, Grand River Aseptic Manufacturing Grand Rapids, Michigan, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Grand River Aseptic Manufacturing (“GRAM” or the “Company”), a portfolio company of Arlington Capital Partners, today announced the promotion of Denis Johnson to Chief Executive Officer, effective September 1, 2025. Mr. Johnson has served as President of GRAM since March 31, 2025. In this new role, Mr. Johnson will lead GRAM’s next phase",
    "url": "https://finnhub.io/api/news?id=bc8fead22d6ece91361a69aaa7b25830a0dd3ec121a87a8a0caa9fd2c27163d5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756821600,
      "headline": "Grand River Aseptic Manufacturing (GRAM) Appoints Denis Johnson as Chief Executive Officer",
      "id": 136612898,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Effective September 1, 2025 Denis Johnson, CEO Denis Johnson, CEO, Grand River Aseptic Manufacturing Grand Rapids, Michigan, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Grand River Aseptic Manufacturing (“GRAM” or the “Company”), a portfolio company of Arlington Capital Partners, today announced the promotion of Denis Johnson to Chief Executive Officer, effective September 1, 2025. Mr. Johnson has served as President of GRAM since March 31, 2025. In this new role, Mr. Johnson will lead GRAM’s next phase",
      "url": "https://finnhub.io/api/news?id=bc8fead22d6ece91361a69aaa7b25830a0dd3ec121a87a8a0caa9fd2c27163d5"
    }
  },
  {
    "ts": null,
    "headline": "J&J publishes new data from DanGer Shock randomized control trial",
    "summary": "Johnson & Johnson reports late breaking clinical science data, presented at the European Society of Cardiology Congress and simultaneously published in the New England Journal of Medicine, finds at up to 10 years, when compared to standard care, routine use of Impella CP in patients who have had a heart attack with cardiogenic shock leads to an absolute mortality reduction of 16.3%. When compared to the control arm at 10 years, Impella CP patients gained an average of 600 additional days alive,",
    "url": "https://finnhub.io/api/news?id=5cb2519e5a28a94a18529d0ed83e56aa43e739aec82079339a1ce4c9df3c83be",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756820419,
      "headline": "J&J publishes new data from DanGer Shock randomized control trial",
      "id": 136612899,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson reports late breaking clinical science data, presented at the European Society of Cardiology Congress and simultaneously published in the New England Journal of Medicine, finds at up to 10 years, when compared to standard care, routine use of Impella CP in patients who have had a heart attack with cardiogenic shock leads to an absolute mortality reduction of 16.3%. When compared to the control arm at 10 years, Impella CP patients gained an average of 600 additional days alive,",
      "url": "https://finnhub.io/api/news?id=5cb2519e5a28a94a18529d0ed83e56aa43e739aec82079339a1ce4c9df3c83be"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson Unveils Results from the VARIPURE Substudy of SECURE, a Real-World Study on VARIPULSE™ Platform, at 2025 European Society of Cardiology (ESC) Congress",
    "summary": "Johnson & Johnson (NYSE: JNJ) -- Johnson & Johnson MedTech, a global leader in cardiac arrhythmia treatment, today announced acute safety and effectiveness results from the VARIPURE substudy of SECURE, evaluating the VARIPULSE™ Platform in pulsed field ablation (PFA) procedures for atrial fibrillation (AF). The real-world data, presented at the 2025 European Society of Cardiology (ESC) Congress in Madrid, demonstrated a strong safety profile, high acute effectiveness and procedural efficiency wi",
    "url": "https://finnhub.io/api/news?id=53d22eac5267570ce743da0285f0c8d0af8afd8b7cb64b709f93286e24506079",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756818000,
      "headline": "Johnson & Johnson Unveils Results from the VARIPURE Substudy of SECURE, a Real-World Study on VARIPULSE™ Platform, at 2025 European Society of Cardiology (ESC) Congress",
      "id": 136604068,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (NYSE: JNJ) -- Johnson & Johnson MedTech, a global leader in cardiac arrhythmia treatment, today announced acute safety and effectiveness results from the VARIPURE substudy of SECURE, evaluating the VARIPULSE™ Platform in pulsed field ablation (PFA) procedures for atrial fibrillation (AF). The real-world data, presented at the 2025 European Society of Cardiology (ESC) Congress in Madrid, demonstrated a strong safety profile, high acute effectiveness and procedural efficiency wi",
      "url": "https://finnhub.io/api/news?id=53d22eac5267570ce743da0285f0c8d0af8afd8b7cb64b709f93286e24506079"
    }
  },
  {
    "ts": null,
    "headline": "Innovative Health Prevails in Lawsuit Against J&J's Biosense Webster for Restraint of Trade",
    "summary": "Innovative Health, Inc. today announced that the company has prevailed in U.S. District Court in its lawsuit against Johnson & Johnson's Biosense Webster medical device unit. The judge's final decision includes a permanent injunction against Biosense Webster's anticompetitive conduct in the reprocessing space, following a jury verdict for Innovative Health that resulted in an award of $442 million in damages.",
    "url": "https://finnhub.io/api/news?id=0bf91eb56873d0efbd35f0cda187073254e8973ae7cc4b429f13af51d341e98e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756814400,
      "headline": "Innovative Health Prevails in Lawsuit Against J&J's Biosense Webster for Restraint of Trade",
      "id": 136604069,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Innovative Health, Inc. today announced that the company has prevailed in U.S. District Court in its lawsuit against Johnson & Johnson's Biosense Webster medical device unit. The judge's final decision includes a permanent injunction against Biosense Webster's anticompetitive conduct in the reprocessing space, following a jury verdict for Innovative Health that resulted in an award of $442 million in damages.",
      "url": "https://finnhub.io/api/news?id=0bf91eb56873d0efbd35f0cda187073254e8973ae7cc4b429f13af51d341e98e"
    }
  },
  {
    "ts": null,
    "headline": "UK Ligation Devices Market Analysis Report 2025-2033, with Profiles of Welfare Medical, Grena, Medtronic, Fannin, BioSpectrum, Teleflex, LocaMed, Johnson & Johnson, Boston Scientific, and more",
    "summary": "The UK ligation devices market promises growth due to rising chronic diseases, an aging population necessitating surgeries, and advancements in minimally invasive techniques. Demand for precise devices is rising, bolstered by NHS modernization and enhanced training, highlighting opportunities for innovation and adoption.Dublin, Sept. 02, 2025 (GLOBE NEWSWIRE) -- The \"UK Ligation Devices Market Size, Share & Trends Analysis Report By Product (Appliers, Accessories), By Application (Gastrointestin",
    "url": "https://finnhub.io/api/news?id=d8414e02959e1a4a644c774415c08cc24c1fe9717c91bd5456f48d96d4b59fd2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756807920,
      "headline": "UK Ligation Devices Market Analysis Report 2025-2033, with Profiles of Welfare Medical, Grena, Medtronic, Fannin, BioSpectrum, Teleflex, LocaMed, Johnson & Johnson, Boston Scientific, and more",
      "id": 136604070,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "The UK ligation devices market promises growth due to rising chronic diseases, an aging population necessitating surgeries, and advancements in minimally invasive techniques. Demand for precise devices is rising, bolstered by NHS modernization and enhanced training, highlighting opportunities for innovation and adoption.Dublin, Sept. 02, 2025 (GLOBE NEWSWIRE) -- The \"UK Ligation Devices Market Size, Share & Trends Analysis Report By Product (Appliers, Accessories), By Application (Gastrointestin",
      "url": "https://finnhub.io/api/news?id=d8414e02959e1a4a644c774415c08cc24c1fe9717c91bd5456f48d96d4b59fd2"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson (JNJ)’s Carvykti Sales Skyrocket 100% Amid Specialty Medicine Growth",
    "summary": "We recently compiled a list of the 10 High Growth Pharma Stocks That Are Profitable in 2025. Johnson & Johnson is placed second among them. Johnson & Johnson (NYSE:JNJ), a global leader in pharmaceuticals, medical devices, and consumer health, continues to drive growth in 2025 through strategic investments in innovation and domestic manufacturing. The company […]",
    "url": "https://finnhub.io/api/news?id=e827f6cad515c17840d558a84c68e97fd4a3da0fe42fdde77017b63f331c9b1d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756801622,
      "headline": "Johnson & Johnson (JNJ)’s Carvykti Sales Skyrocket 100% Amid Specialty Medicine Growth",
      "id": 136604071,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "We recently compiled a list of the 10 High Growth Pharma Stocks That Are Profitable in 2025. Johnson & Johnson is placed second among them. Johnson & Johnson (NYSE:JNJ), a global leader in pharmaceuticals, medical devices, and consumer health, continues to drive growth in 2025 through strategic investments in innovation and domestic manufacturing. The company […]",
      "url": "https://finnhub.io/api/news?id=e827f6cad515c17840d558a84c68e97fd4a3da0fe42fdde77017b63f331c9b1d"
    }
  }
]